Voyager Therapeutics
VYGR
125 hedge funds and large institutions have $796M invested in Voyager Therapeutics in 2019 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 47 increasing their positions, 27 reducing their positions, and 16 closing their positions.
716% more call options, than puts
Call options by funds: $7.26M | Put options by funds: $890K
113% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 16
74% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 27
51% more capital invested
Capital invested by funds: $526M → $796M (+$271M)
13% more funds holding
Funds holding: 111 → 125 (+14)
4.7% less ownership
Funds ownership: 84.22% → 79.52% (-4.7%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$61.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$19M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$8.34M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$8.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$13.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.18M |
| 3 |
HCM
Highline Capital Management
New York
|
-$6.68M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$5.94M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.72M |
VYGR Hedge Fund Activity: Q2 2019 in Review
125 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2019, worth a combined $796M — up 51% from $526M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new VYGR positions and 16 closed out — a net gain of 18 holders — while 47 added to existing stakes and 27 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $61.3M. The largest seller was Armistice Capital, cutting an estimated $13.7M.
- 125 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2019, up from 111 in Q1 2019.
- Funds reported $796M of Voyager Therapeutics stock for Q2 2019, up 51% quarter-over-quarter.
- 34 funds opened new Voyager Therapeutics positions in Q2 2019 and 16 closed out, a net change of +18 holders.
- The largest Voyager Therapeutics buyer in Q2 2019 was Bellevue Group, an estimated $61.3M added.
- The largest Voyager Therapeutics seller in Q2 2019 was Armistice Capital, an estimated $13.7M sold.
Based on aggregated 13F filings for Q2 2019.